Do analysts recommend ZIVO or MNOV?

MediciNova has a consensus price target of $8.33, indicating a potential upside of 526.57%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts recommend ZIVO or CING?

Cingulate has a consensus target price of $27.33, suggesting a potential upside of 453.31%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ZIVO or CING more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Cingulate N/A -365.15% -158.55%

Do analysts rate CLNN or ZIVO?

Clene presently has a consensus price target of $33.25, indicating a potential upside of 518.03%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Clene is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CLNN or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts rate ZYBT or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, ZYBT or ZIVO?

ZIVO Bioscience has lower revenue, but higher earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 6.72 -$9.98M N/A N/A ZIVO Bioscience $15.85K 1,047.85 -$7.78M -$1.71 N/A

Is ZYBT or ZIVO more profitable?

Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A ZIVO Bioscience N/A N/A -2,240.92%

Do analysts recommend SCLX or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SCLX or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets Scilex -1,110.17% N/A -143.55% ZIVO Bioscience N/A N/A -2,240.92%

ZIVO Bioscience (ZIVO) Competitors

$4.00 0.00 (0.00%)

As of 08/4/2026

Compare

ZIVO vs. MNOV, CING, CLNN, ZYBT, and SCLX

Should you buy ZIVO Bioscience stock or one of its competitors? MarketBeat compares ZIVO Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZIVO Bioscience include MediciNova (MNOV), Cingulate (CING), Clene (CLNN), Zhengye Biotechnology (ZYBT), and Scilex (SCLX). These companies are all part of the "pharmaceuticals" industry.

How does ZIVO Bioscience compare to MediciNova?

ZIVO Bioscience (NASDAQ:ZIVO) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, MediciNova had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for MediciNova and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.67 beat MediciNova's score of 0.00 indicating that ZIVO Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
ZIVO Bioscience	Positive
MediciNova	Neutral

ZIVO Bioscience has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. ZIVO Bioscience's return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
MediciNova	-1,962.98%	-27.28%	-25.24%

ZIVO Bioscience has higher earnings, but lower revenue than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,047.85	-$7.78M	-$1.71	N/A
MediciNova	$410K	159.66	-$12M	-$0.23	N/A

ZIVO Bioscience has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

MediciNova has a consensus price target of $8.33, indicating a potential upside of 526.57%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

MediciNova beats ZIVO Bioscience on 9 of the 17 factors compared between the two stocks.

How does ZIVO Bioscience compare to Cingulate?

ZIVO Bioscience (NASDAQ:ZIVO) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, Cingulate had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.67 beat Cingulate's score of 0.00 indicating that ZIVO Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
ZIVO Bioscience	Positive
Cingulate	Neutral

ZIVO Bioscience has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

ZIVO Bioscience has higher revenue and earnings than Cingulate. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,047.85	-$7.78M	-$1.71	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Cingulate has a consensus target price of $27.33, suggesting a potential upside of 453.31%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ZIVO Bioscience's return on equity of 0.00% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Cingulate	N/A	-365.15%	-158.55%

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ZIVO Bioscience beats Cingulate on 8 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Clene?

Clene (NASDAQ:CLNN) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Clene has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

In the previous week, ZIVO Bioscience's average media sentiment score of 0.67 beat Clene's score of 0.00 indicating that ZIVO Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Clene	Neutral
ZIVO Bioscience	Positive

Clene presently has a consensus price target of $33.25, indicating a potential upside of 518.03%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Clene is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has lower revenue, but higher earnings than Clene. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	343.78	-$26.17M	-$3.20	N/A
ZIVO Bioscience	$15.85K	1,047.85	-$7.78M	-$1.71	N/A

ZIVO Bioscience has a net margin of 0.00% compared to Clene's net margin of -25,009.70%.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
ZIVO Bioscience	N/A	N/A	-2,240.92%

23.3% of Clene shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Clene and ZIVO Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Zhengye Biotechnology has a beta of -2.72, meaning that its stock price is 372% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

In the previous week, Zhengye Biotechnology had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Zhengye Biotechnology and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.67 beat Zhengye Biotechnology's score of 0.00 indicating that ZIVO Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
ZIVO Bioscience	Positive

12.8% of ZIVO Bioscience shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ZIVO Bioscience has lower revenue, but higher earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	6.72	-$9.98M	N/A	N/A
ZIVO Bioscience	$15.85K	1,047.85	-$7.78M	-$1.71	N/A

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
ZIVO Bioscience	N/A	N/A	-2,240.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

ZIVO Bioscience beats Zhengye Biotechnology on 6 of the 10 factors compared between the two stocks.

How does ZIVO Bioscience compare to Scilex?

Scilex (NASDAQ:SCLX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Scilex has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

In the previous week, Scilex had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Scilex and 0 mentions for ZIVO Bioscience. Scilex's average media sentiment score of 0.67 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Scilex	Positive
ZIVO Bioscience	Positive

69.7% of Scilex shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has lower revenue, but higher earnings than Scilex. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.83	-$358.73M	-$40.47	N/A
ZIVO Bioscience	$15.85K	1,047.85	-$7.78M	-$1.71	N/A

ZIVO Bioscience has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Summary

Scilex beats ZIVO Bioscience on 7 of the 12 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZIVO vs. The Competition

Export

Metric	ZIVO Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.61M	$11.67B	$6.90B	$12.86B
Dividend Yield	N/A	2.73%	2.60%	10.00%
P/E Ratio	-0.82	791.56	280.82	25.41
Price / Sales	1,047.85	740.97	599.65	90.78
Price / Cash	N/A	71.54	72.11	49.40
Price / Book	-4.94	10.85	12.95	6.08
Net Income	-$7.78M	$2.82B	$3.49B	$348.07M
7 Day Performance	0.00%	3.34%	3.57%	4.71%
1 Month Performance	-20.00%	-1.90%	-2.50%	-2.12%
1 Year Performance	-70.37%	193.72%	73.94%	20.58%

ZIVO Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZIVO ZIVO Bioscience	N/A	$4.00 flat	N/A	-70.4%	$16.61M	$15.85K	N/A	10
MNOV MediciNova	1.4259 of 5 stars	$1.34 flat	$8.33 +521.9%	-3.7%	$65.96M	$410K	N/A	10	Positive News
CING Cingulate	1.7776 of 5 stars	$4.76 +0.0%	$27.33 +474.1%	-12.7%	$63.98M	N/A	N/A	20
CLNN Clene	2.0591 of 5 stars	$4.99 -1.1%	$33.25 +567.0%	+41.2%	$63.71M	$134K	N/A	100	Gap Up
ZYBT Zhengye Biotechnology	0.2056 of 5 stars	$1.29 -5.5%	N/A	-77.8%	$60.90M	$16.64M	N/A	278	Trading Halted

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. MNOV, CING, CLNN, ZYBT, and SCLX

How does ZIVO Bioscience compare to MediciNova?

Summary

How does ZIVO Bioscience compare to Cingulate?

Summary

How does ZIVO Bioscience compare to Clene?

Summary

How does ZIVO Bioscience compare to Zhengye Biotechnology?

Summary

How does ZIVO Bioscience compare to Scilex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. MNOV, CING, CLNN, ZYBT, and SCLX

How does ZIVO Bioscience compare to MediciNova?

Do institutionals and insiders have more ownership in ZIVO or MNOV?

Does the media refer more to ZIVO or MNOV?

Is ZIVO or MNOV more profitable?

Which has better earnings & valuation, ZIVO or MNOV?

Which has more volatility and risk, ZIVO or MNOV?

Do analysts recommend ZIVO or MNOV?

Summary

How does ZIVO Bioscience compare to Cingulate?

Does the media refer more to ZIVO or CING?

Which has more risk and volatility, ZIVO or CING?

Which has stronger valuation & earnings, ZIVO or CING?

Do analysts recommend ZIVO or CING?

Is ZIVO or CING more profitable?

Do institutionals and insiders hold more shares of ZIVO or CING?

Summary

How does ZIVO Bioscience compare to Clene?

Which has more risk & volatility, CLNN or ZIVO?

Does the media refer more to CLNN or ZIVO?

Do analysts rate CLNN or ZIVO?

Which has higher valuation & earnings, CLNN or ZIVO?

Is CLNN or ZIVO more profitable?

Do institutionals & insiders believe in CLNN or ZIVO?

Summary

How does ZIVO Bioscience compare to Zhengye Biotechnology?

Which has more volatility & risk, ZYBT or ZIVO?

Does the media refer more to ZYBT or ZIVO?

Do institutionals and insiders have more ownership in ZYBT or ZIVO?

Which has preferable valuation and earnings, ZYBT or ZIVO?

Is ZYBT or ZIVO more profitable?

Do analysts rate ZYBT or ZIVO?

Summary

How does ZIVO Bioscience compare to Scilex?

Which has more risk & volatility, SCLX or ZIVO?

Does the media prefer SCLX or ZIVO?

Do insiders and institutionals have more ownership in SCLX or ZIVO?

Do analysts recommend SCLX or ZIVO?

Which has better earnings and valuation, SCLX or ZIVO?

Is SCLX or ZIVO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools